GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Patients in the belimumab group outpaced those on standard immunotherapy as early as 3 months in meeting the primary outcome and were more likely to sustain it through 24 months (HR = 0.631; 95% ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus (SLE) when added to standard therapy, according to study results ...

Patients with non-renal SLE who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.

Long-term treatment with belimumab slows the key drivers of organ damage — disease activity, severe flares, and glucocorticoid exposure — in patients with systemic lupus erythematosus (SLE ...

Benlysta (belimumab) Analytical Perspective • In-depth Benlysta (belimumab) Market Assessment This report provides a detailed market assessment of Benlysta (belimumab) in Seven Major Markets, i ...

Belimumab is an anti-BAFF monoclonal antibody that has been approved by the FDA to treat systemic lupus erythematosus (SLE). BAFF and interleukin 6 expression have been shown to beheightened in ...

A new study finds that belimumab (Benlysta®) is an effective therapy option for people with cutaneous lupus erythematosus (CLE), a form of lupus that affects the skin. This study highlights that ...

The authors said belimumab did not spark statistically significant benefits either in terms of reducing relapses (1.4 in the 6 months on therapy vs 2.0 in the 6 months before therapy; P = .21) or ...

Belimumab is a monoclonal antibody, prescribed for active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy. Belimumab Interaction with 77 drugs.

Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 ...